FDA Committee Recommends Moderna's mRNA Flu Vaccine for Adults 50 and Over

1-Minute Brief

This recommendation marks a potential shift in influenza prevention by introducing mRNA technology for older adults.

Key Facts

• All nine members of the FDA advisory committee voted unanimously in favor of the vaccine recommendation.
• The vaccine under consideration is developed by Moderna and uses mRNA technology.
• The recommendation specifically applies to adults aged 50 and older.
• The FDA panel discussed the vaccine as a new approach to flu immunization.
• This is the first FDA committee recommendation for a flu vaccine since 2023.

What Happened

An FDA advisory committee unanimously recommended Moderna's mRNA-based influenza vaccine for adults 50 and older after deliberations.

Why It Matters

If authorized, this would be the first flu vaccine using mRNA technology available to older adults in the U.S., potentially changing the landscape of influenza vaccination.

What's Next

The FDA will review the committee's recommendation and decide whether to authorize the vaccine for public use.